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~ A  Coaxial Catheter for Prevention of System 
Distal Embolizstlon 
S,N, Oesferle, D.S. Balm, M, Hayase, S.R, Ramee, P.S. Tetrsteln, 
R, Vtrrr~nl, Stanford University Medical Center, Stanford, California, USA 
Angloplasty tAP) of aged vein grafts has been substantially hindered by 
the common occurrence of distal embollzatlon (DE) associated with "no 
reflow" end myocardial Infamtlon (MI), Carotid Angloplasfy (CA) is similarly 
compromised by the distinct potential for DE with ¢embrovascular Injury. 
We have evaluated a coaxial catheter system that utilizes a novel 0.014" 
guldewlre (GW) mounted with an elestomerio distal occlusion balloon (DB) to 
preclude DE of debris following AP end slanting over this device, The system 
allows the exchange of vidunlly ell commerolally available stonf and AP 
systems over the GW while the DB is inflated, A monorail aspiration catheter 
evacuates debris prior fo d.llatlon of the DB, Eight porcine studies at 4 
institutions were conducted to assess the performance of the system during 
engloplesty and 8tent deployment in the general vasculafure, Occlusion times 
ranged between 2 end 4 minutes, Evacuation rates averaged 1 cclsec. All 
eight animals tolerated the procedure (DB Inflation, AP catheter delivery, 
exchange for slant device, slant delivery, aspiration, DB defletlon) and no 
complications were observed, In three studies, occlusion and aspiration were 
pedormed In a vassal without antecedent AP or slanting fo determine, by 
htsfologlo analysis, If any morphologlc chnnges occur after the use of the 
system, The endothelial loss observed were similar to the changes observed 
r~fter the passage of wires and angloptosty cathefem wifh0uf inflation end are 
of no ollnlcal elgnlflcanae, 
Conclusion: The s~fe and eftlclont application of the technology in this 
study, shows premise in mitigating the Incidence of DE in degenerated and 
diseased vessels during engloplasty end stenftng, 
~ A n  Emboll Containment System for Saphenous 
Vein Graft Angloplasty 
J,G, Webb, R,G, Corers, K. Lo, C. Li, C. McOueen, A. Dodek, R. VirmanL 
Sf, Paul~ Hospital, Vancouver, Canada 
Backgreur~: Distal embollzation and "no reflow" are frequent and important 
complications during PTCA of diseased 8aphonous vein grafts, 
^~thocts: The Percusurg8 ~ embotl containment system consists of a 
hollow 0.014" PTCA wire Incoq0oraflng a compliant Inflatable distal occlusion 
balloon, During occlusion of the distal graft, PTCA can be pedormed in a 
standard manner, A monorail aspiration catheter allows removal of potentially 
embolle debris prior to deflation of the occlusive balloon. 
Results: PTCA was performed in 10 sephenous vain grafts (graft age 
10 ~ 4 yra). NIH (9), Multllmk (3). Be (1) stents measuring 9 to 35 mm in 
length were implanted. Prophylactic a~txlmab and/or thrombolytics were not 
utilized. Minimum lumen diameter increased from 0.4 ± 0.4 to 3.3 ± 0.4 ram. 
No pt developed new ECG evidence of infarction, required surgery, or died. 
The duration of gmlt occlusion required to allow dllaticn and aspiration 
was 173 :~ 67 sac, decreasing as experience was gained. Mean aspirate 
volume was 20 ml. 
Initial TIMI flow grade was 0 in 1 pt. 1 in 2 pts, 2 in 2 pts end 3 in 5 pts. TIMI 
flow post-precedure was grade 3 in all pts. Bulky thmmbus visible in 2 pts 
pro-procedure was not visible post-procedure. In one pt with visible thrombus 
transient intra-procedural distal occlusion occurred associated with a rise in 
CK to 432 and CK MB to 32 U/L, In 9 of 10 pts CK and CK-MB remained 
normal (-~260 U/L and <6 ug/L units/mr). 
Grossly visible debris was retrieved in all pts. Scanning electron mi- 
croscopy revealed tissue fragments of mean length 230 um (range 50 to 110 
urn) and width 80 um (range 16 to 525 urn). Plaque material was confirmed by 
light microscopy and consisted predominantly of cholesterol clefts, lipid-rich 
macrophages, fibrous caps, necrotic core and fibrin material. 
Conclusion: ~'he Pemusurge" emboli containment system is compatible 
with routine angioplasty procedures, is capable of containing and retrieving 
atherosclerotic and thrombotic debris, and may aid in the prevention of distal 
embolization and no reflow in diseased saphenous vein grafts. 
~ Intra~uminsl Low Power red Laser Therapy: Late 
Follow-up 
I. De Scheerder, b Chevalier, U. Kaul, M. Perle, H. Sahota, M, Keelan, 
N. Kipshidze. University Hospitals, Leuven, Belgium: Medical College of 
Wisconsin, Milwaukee. Wisconsin, USA 
Intrsltlminal ow power red laser irradiation (IRLI) accelerates endothelial 
growth and by modulating smooth muscle cell migration and proliferation, 
inhibits restenosis in various animal models. 
We report long-term results of IRLI in 189 patients. All received IRLI using 
a laser-balloon (Global Therapeutics, Broomfield, CO) at power of 10 mW 
for 3 one-minute doses after PTCA and/or sleeting procedures. Indications 
for IRII were: de novo lesions (37 pts), suboptimal PTCA results (57 pts), 
ball out situation (12 pts), bypass graft (2 pts), recurrent restenosls (40 pts), 
and In-stoat restenosis (41 pts). Angiogmphtc haracteristics" mean vessel 
diamsier 3,0 • 0.7 ram, lesion length 9.3 :t: 0.5 mm, type B and C lesions 
(83,5%), and diffuse disease (32%), We observed no major complications 
associated with IRLI following interventions and early follow-up. 
Anglographlc follow.up at 6 months (71 pts) revealed restanosls (sfenosie 
>50% luminal diameter) rate in ell groups of 16,9%, Moreover, restenosis 
refe was only 7,8% in arteries (n = 38) diameter >3,0 mm (late loss Index = 
0,27 :t: 0,1 mm), In arteries (n = 33) dlemefor .~3,0 mm, restenosls occurred 
in 26% (late loss Index - 0,35 :t: 0,15 ram), Re~tenosls in 44 pie with recurrent 
and In-slant resfenosl8 was 22%, 
We conclude IRLI reduces luminal renarrowlng in pts following coronary 
tnferventions. 
• Anglo Jet  Thrombectomy Catheter for  Acute 
Myo©a~llal InfMctlon 
Y, Nakegewe, $, Mnfsuo, 1", lbmum, H, Yokel, N, Hamasaki, T, Kimum, 
H, Nosnke, M, NobuyoshL Kekura Memon~It Hospital, Kitakyz~hu, Japan 
Ba~grouncl: Acute Myocardial Infemfion (AMI) is associated with ietmcore. 
nery fhmmbus, Intmcomnary thmmbus has been identified e8 e predictor 
o! unlavorebla outcome after PTCA, and also has been considered to boa 
oontralndlc(tflon for 8tentlng, AngloJet Ihmmlxctomy catheter (AJ) removes 
thrombus by rhootytic suction, 
Method: Between Nov, g6 and Aug, g7,240 AMI patients (eta) were admit. 
ted, and 20 pts (11%) received AJ, (mean age 61 • 11, male 88%,), Infar¢;tioll 
arteries were 18 RCA (69%), 5 LAD (19%), 1 LCX (4%) and :2 SVG (8%). 
Results: Of the 26 pt8, 24 pts (92%) received AJ as a planned treatment 
according to initial angiogrem suggesting presence of massive thmmbus 
and all of them were successful, and other 2 pts (8%) received AJ as a 
bailout treatment for distal embolism after direct balloon angloplasty and 
these 2 cases ware tailed. Of the 24 successful AJ, 23 eta (96%) recetved 
adjunctive balloon and 9 pts (38%) received subsequent slanting and one Pt 
(4%) finished with AJ alone. One pt (4%) received adjunctive t-PA infusiOn 
for minor distal embolism, There was no in.hospital death and no AJ related 
MI, One pt (4%) received CABG due to balloon rapture of adjunctive PTCA. 
There was no acute or subacute thrombosis alter stenting. Quantitative 
angiography data (CMS system) showed significant improvement of TIMI 
flow grade and reduction of thrombos length alter AJ. 
Initial Post AJ Final P-value 
TiMI grade 0,50 z 0.19 2.88 ± 0.92 2.88 • 0.9'> .0.0001 
RefeTence (mm) 3.82 ~ 0.86 3,83 ± 0.80 395 ± 074 NS 
MLD (ram) 023 ± 0.38 1 16 ± 0.59 2.79 ± 065 ~O 000r 
%Diameter stenosis 930 ± 12.0 57 1 ~: 14 8 289 ± 12 5 -0 0001 
Thrombus length (ram) 21.6 ± 13.6 3.6 ± 6,7 0 -00001 
Conclusion: 1) AJ could be used successfully in removing thrombus m 
pt with AMi. 2) AJ seems to have no bailout effect for distal embolism alter 
balloon angioplasty. 3) Thrombus removal makes subsequent stealing safe 
and uncompt¢ated. Angiographic follow-up study is ongoing. 
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~ Abc lx lmab Can Freely Redistr ibute Between 
GPIIb/III~I and '~'v/~3 
M.T. Nakada, S,H. Tam, E.T. Lance, R.E. Jordan. Cenfocor, Malvem, PA, 
USA 
In addition to acute inhibition of platelet (PLT) function during infusion, ab- 
ciximab (07E3 Fab, ReoPre TM) has a prolonged PLT-bound half-life after 
termination of the infusion which is associated with a slow recovery of PLT 
aggregation, This is attributable to the continuous redistribution of abciximab 
among PL ,~s as measured by in vitro and ex rive FACS analysis. Abciximab 
binds and blocks not only PLT GPIIb/llla but also the related integrin cxv/~ 3 
which mediates vascular cell proliferation and PLT thrombin generation. The 
objective of this study was to determine if abciximab could redistribute from 
GPllb/llla to -./~3. FITC-abciximab-boundHEL cells (expressing GPIIb/illa) 
were mixed with unlabeled c~v/~3-expressing M21 cells and samples were 
fixed at various times for FACS analysis. Data are representative of 4 sep- 
arate experiments. Abciximab redistributed in vitro from GPIIb/llla to -v/~3 
with redistribution complete by 2 hours. Equivalent redistribution occurred 
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f!om GP!!b/llla to GPIIb/IIIa. from ,~/b to ,,,/~ and from -~P3 to GPltb/llla. 
¢ellecting th~ c0mpa~ affinity of ~x imab for both integrins. 
Conc/us/on: Abciximab can redisthbute between GPllb/llla and . ,~  re- 
ceplora/n vitro, suggesting that abctximab may have proPmged effects on 
~/~ on vascular cells in addition to sustained inhibition of PLT GPIIb/llla. 
• ~t ing  With Abcixlmab (ReoPro'") OeciCases 
Target Lesion Revascularllaflon 
S.K, Shatma, A. Kini, G, Oangas, R. VkJhun, Y. Rajawat, S. Ouvvun, 
J D. Marmur, J.A. Ambrose. Mount Sinai Hospital, New York. USA 
Abciximab (Reopre") has been shown to decrease acute ischemic com- 
plcatK~ns and reduce clinical restenoais following balloon angioplasty and 
coronaw atherectomy. Whether ResPro offers similar benefit after stentmg 
has not been evaluated. We analyzed the 30-day incidence of malor adverse 
cardiac events (MACE) and the need for target lesion revasculanzation (TLR) 
in 388 consecutive stent patients: 78 with ReoPro and 310 wdbout ReoPre. 
Patients with hail-out slanting were excluded. 
Results: As expected, ReoFro was used more frequently in MI and rest 
angina cases ('acute syndromes') and in the setting of multiple stents and 
muttwesset intervention. The incidence of 30-day ~CE did not differ with 
ReoPro. However, the 9-month TLR was sigmticantly lower in the group 
treated with stent plus Reopro compared to stent alone: 
Stent + ReoPro n = 78 Slant alone n = 310 p 
Acute syndromes 68*o 43% 001 
Mu tllless~l $lentlr~j 20% 10% 0 03 
Multiple stents :29°0 21% 0 01 
Procedural Success 98 7°0 98 3% NS 
30-day MACE 1 2=° 22% NS 
Vasculal complications 38% I 6% NS 
TLR 19% 30% 0.02 
MACE = acute/subacute stont hrombosis. Q- ML CABG or death 
Conclusion: The use of RecPro during stenting decreases long-term TLR 
compared to stenting alone. These results were evident even though the 
ReoPro treated group was at higher risk. ReoPre did not affect significantly 
the already low short-term MACE after stenting. Based on these preliminary 
results, the effect of ReoPro on angiographic in-stent restenosis warrants 
prospentLve investigation. 
I 1088-1001 Act ivat ion  of  Platelets in P latelet-r ich Plasma by  
Rotab lat ion  Is Speed Dependent  and Can Be 
Inhib i ted by Abc ix imab (c7E3 Fab; ReoPro") 
MS. Williams, B.S. Coller, H.J. V~n~nen. L.E. Scudder, J.D. Marmur. 
Mount Sinai Hospital New ~brk, New York, USA 
Background: Rotational atherectomy may be complicated by the =no*reflow" 
phenomenon. Because platelet activation may contribute to this complication. 
we developed an in vitro system to test the effect of rotablation on platelets 
in the absence or presence of GPIIb/llla blockade with abciximab. 
Methods: Platelet-nch plasma (PRP) was prepared from 22 healthy hu- 
man volunteers. PRP was divided into four samples: no treatment, 6D1 
(anti-GPIb), abciximab (anti- GPIIb/llla + ~vB3), and abeiximab + 6D1. Sam- 
ples were pumped through a flow chamber containing a 2.5 mm burr rotating 
at various speeds, and then placed in an aggregometer and stirred at 3~C. 
Results: PRP samples tested in the absence of antibody underwent more 
rapid and extensive aggregation when rotablated at 150 and 180k rpm as 
compared to 0 rpm (p .- 0.00001 at both speeds). Preincubation of platelets 
with c7E3 Fab decreasnd the slope of aggregation at each retaliation speed 
(p = 0,09 for 70k and p .- 0,0001 for both 150 and 1801(rpm). The msuffs 
are plotted as mean slope of aggregation • SD vs, rot~blatlon spe l l  Both 
light and electron microscopy revealed rotablat~n~nduced platelet damage 
at 150 and tS0k rpm 
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Conclt~q:  Rolablalion causes speed-depeedenl plaleiel actlvahon in 
PRP which can be ~igniflcantly reduced by pre.lreating PRP with abcil, 
~mab These data s~tggest thai prelreatment of patients w~th abciximab may 
decrease rotablation-induced platelet aggregation dunng mtat~l  atherec- 
ferny, 
I 1088-10111 lbC iX l lb  Reduces the Need for Balt,oui 
Stenting Dur ing  I~rimary lng lop lu ty ,  
RAPPORT Tr ia l  
LA. Barr, S.J. Branor, A.A. Jones, DJ. Mofitemo, M.B. Effron, EJ. Topoi. 
For the RAPPORT Investigators. Midwest Hearl Reseanch, Lombard. 
Illin~s, USA 
Background: Primary angmplasty for acute myocardial infarction (MI) is often 
complmated by transient or permanent abrupt vessel Closure due to dis- 
seclrons, rec~l, or thrombosis, whch frequently leads to bail~out stl~'ltit~. 
Abcixinlab, administered before angioplasty, has been shown to reduce the 
nsk of acute vessel closure, but has not been tested dunng primary PTCA. 
Methods: Patents (ptsl with acute MI <12 hr. were randomly allocated 
to placebo (P) or abciximab (A - 0.25 mcg,~g bolus and 12-hour mfusmn 
at 0.125 mcoJkg/min} as an adjunct to pnmery balloon angmplasty. Slanting 
was allowed for large dLseect~ons or acute/threatened vessel closure ('TIMI 
flow <2). 
Results: The need for stenting in the three groups (intention-to.treat -fl-r 
[242 P, 241A], any amount of study drug - DRUG [2131:), 226A], and interven- 
tion with study drag per protocol - I [170P, 179A]) is presented below. 
P A p value RR 
ITT 174% I1 6% 0057 33% 
DRUG 183% 11 5=° 0 031 38% 
I 20 6"* 12 3% 0G22 41'% 
Conclusron: By preventing platetet aggregation at the site of ba,oon 
inflation, abeiximab reduces the need for bail-out stenting dunng primary 
angioplasty for acute myocardial infarction. The effect was most pronounced 
in the group who received abciximab for ;he entire 12-hour period. Cost 
implications and potential for combined abctmmab and pnmary stenting need 
further exploration. 
t 1088-102 ] Abc ix imab Decreases  the Incidence and 
Magnitude of Non-O Wave Myocardial Infarction 
Assoc iated With Rotat ional  A themctomy 
G.A. Braden. WM. Love, RJ. Applegate, TM Young, D.C. Sane. Bm~rnan 
Gray School of Medicine. Winston-Salem. NC, USA 
Creatine kinase (CK) nse/non-Q wave MI (NQMI) is common following ro- 
tational atherectomy (RA) and may be assooated w~th long term adverse 
outcomes. Abciximab (ReoPm) decreases the incidence of NQM! following 
PTCA and DCA, however, the benefits of ReoPro during RA have not been 
previously assessed. Accordingly. we examined the effects of ReoPro on 
acute outcome during RA. 176 pts. received ReoPm (bolus + 12 hr infusion) 
and t50 pts. received heparin (Hep) only between 10/95 and 12/96. ReoPre 
pts. had lower ACT's (340 ± 6) vs. heparin (431 ± 8). p < 0.05. While ReoPro 
treated pts. had more angiographically complex anatomy (AHA/ACC B:~/C 
lesions 47.6% ReoPro vs. 22.9% non-ReoPro, p < 0.001). Vascular access 
complications were similar however more non-ReoPro pts. received trans- 
fusions (15.3% vs. 6.4%. p < 002). Thrembocytoponia (pH <100,000) was 
similar between the two groups (2.6 vs. 2.3%). CK rise following PTCRA: 
peak CK CK A 1-3, N1 ;3~N1 Any AbNt 
ReoPro 149 • 13 86 t 13 14% 3% 17% 
Non-ReoPro 354 +_ 100 278 ~ 9B 18°o 12°o 30% 
P <0.05 . 005 0.06 - 0.05 -005 
